Form 4: Core Scientific Exec Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. reports that executive Todd M. Duchene sold shares of common stock as part of a pre-arranged trading plan.

Summary

• Todd M. Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported transactions involving the sale of company common stock.
• These sales occurred on May 11, 2026, and were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025.
• A total of 10,000 shares were sold in two separate transactions.
• The first transaction involved 2,600 shares sold at a weighted average price of $22.8162, with individual sales ranging from $22.13 to $23.11.
• The second transaction involved 7,400 shares sold at a weighted average price of $23.3916, with individual sales ranging from $23.13 to $23.72.
• Following these transactions, Duchene beneficially owns 1,970,348 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it reports routine executive stock sales under a pre-established plan, which is a standard practice and not indicative of company performance issues.

Negatives

• Executive selling a significant number of shares, even if under a pre-arranged plan, can sometimes be perceived negatively by the market.

Risks

• The Rule 10b5-1 plan is designed to provide an affirmative defense against allegations of insider trading, but the execution of such plans can still be subject to market interpretation.
• The weighted average prices indicate a range of sale prices, suggesting market volatility during the transaction period.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.13 to $23.11, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 to $23.72, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving Rule 10b5-1 plans, are common for executives looking to diversify their holdings or manage personal finances in a structured manner. The execution of such plans can be a routine event, but the volume and timing relative to company news are always scrutinized by investors.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, though the Rule 10b5-1 plan mitigates concerns about insider knowledge.
• Employees: May observe executive compensation and stock ownership trends.
• Management: Demonstrates adherence to established trading policies.

Next Steps

• Continued monitoring of executive trading activity for any further transactions.
• Analysis of Core Scientific's overall financial health and operational performance to contextualize executive shareholdings.

Key Dates

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Executive Transactions, Beneficial Ownership